Older women who received denosumab (Prolia, Amgen) for up to 10 years for osteoporosis had a low risk of osteonecrosis of the jaw (ONJ), although the risk was higher — albeit still quite small — if ...

Osteonecrosis of the jaw (ONJ) is a serious complication for physicians prescribing bone resorption inhibitors to patients with osteoporosis. A session at the recent French Congress of Rheumatology ...

Research has shown that cancer patients on bisphosphonates are at risk of developing osteonecrosis of the jaw (ONJ) and that those on the intravenous form of the drug are at a higher risk compared ...

Osteonecrosis of the jaw (ONJ) is a reported complication of bisphosphonate use. The incidence ranges between 6 and 13% and seems to be higher in people treated with zoledronic acid (ZA) than with ...

Bisphosphonates are potent inhibitors of osteoclastic bone resorption, and are used to treat osteoporosis and bone metastases; however, reported adverse effects include osteonecrosis of the jaw (ONJ).

Researchers at Scottish Rite for Children received a $2.3 million, five-year grant from the National Institutes of Health (NIH) to study how the body repairs bone and restores blood flow in ...

A humanized antibody used in cancer immunotherapy may be associated with a 44-year-old woman developing osteonecrosis of the jaw (ONJ). The case report was published on January 1 in Oral Surgery, Oral ...

Osteonecrosis of the jaw (ONJ) is a debilitating bone condition that affects the jaws and occurs as a result of reduced local blood supply to the bone. Today, experts released a research report that ...

The use of antiresorptive drugs for tumor-related disorders and oral, but not injectable, corticosteroids were associated with an increased risk for osteonecrosis of the jaw among patients with ...

A systematic review was conducted to select founding articles and assign level of evidence and grade recommendations. The authors’ statement that “formal quality assessment of included studies was not ...